• About
  • Blog
  1. Home
  3. Blog
  5. Companies
  7. BVXV

BiondVax Pharmaceuticals Ltd.(BVXV)

NASDAQ Capital Market
Sector: Healthcare | Industry: Biotechnology
BiondVax Pharmaceuticals Ltd. logo

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Latest News & Analysis

Scinai Immunotherapeutics strategic shift, market challenges, and NanoAbs technology in biotech sector. Financial analysis and future outlook.
Feb 21, 2025

Scinai Immunotherapeutics: Strategy Shift and Market Challenges

A comprehensive intraday update on Scinai Immunotherapeutics (SCNI), formerly BiondVax, focusing on its strategic shift, financial challenges, and market positioning.

Read more →

Professional-grade financial analysis tools for informed investment decisions.

Product

  • Features
  • Pricing

Resources

  • Blog
  • Knowledge Base
  • Community
  • Market Data

Company

  • About
  • Careers
  • Contact
  • Partners

Legal

  • Privacy
  • Terms
  • License
  • Security

© 2025 Monexa. All rights reserved. Market data provided by financial exchanges and may be delayed as specified by financial exchanges or our data providers.